SAGE - Sage Therapeutics GAAP EPS of -$1.80 misses by $0.15 revenue of $7.9M beats by $2.71M
2024-04-25 06:34:32 ET
More on Sage Therapeutics
- Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade)
- SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript
- Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Sage Therapeutics Q1 2024 Earnings Preview
- BofA downgrades Sage to underperform, cites failed Parkinson's study